- Australia
- /
- Healthtech
- /
- ASX:IME
ImExHS First Half 2025 Earnings: AU$0.062 loss per share (vs AU$0.034 loss in 1H 2024)
ImExHS (ASX:IME) First Half 2025 Results
Key Financial Results
- Revenue: AU$13.7m (down 1.6% from 1H 2024).
- Net loss: AU$3.00m (loss widened by 98% from 1H 2024).
- AU$0.062 loss per share (further deteriorated from AU$0.034 loss in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ImExHS Earnings Insights
Looking ahead, revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia.
Performance of the Australian Healthcare Services industry.
The company's shares are down 8.3% from a week ago.
Risk Analysis
Before you take the next step you should know about the 5 warning signs for ImExHS (2 are a bit concerning!) that we have uncovered.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:IME
ImExHS
Offers cloud-based medical imaging solutions in Australia and internationally.
Excellent balance sheet with moderate risk.
Market Insights
Community Narratives


